Estimating and comparing the clinical and economic impact of paediatric rotavirus vaccination in Turkey using a simple versus an advanced model

Vaccine

Volumn 31, Issue 6, 2013, Pages 979-986

  Bakir, Mustafa ^a   Standaert, Baudouin ^b   Turel, Ozden ^c   Bilge, Zeynep Ece ^d   Postma, Maarten ^e  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b GSK   (Belgium)

^c Kanuni Sultan Suleyman Training and Research Hospital   (Turkey)

^d GLAXOSMITHKLINE   (United Kingdom)

^e UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Economic evaluation; Model; Paediatric; Rotavirus; Turkey; Vaccination

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; CHILD; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DIARRHEA; DRUG EFFICACY; HEALTH CARE COST; HOSPITAL CARE; HOSPITAL INFECTION; HUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL; TURKEY (REPUBLIC); VACCINATION;

CHILD; CHILD, PRESCHOOL; COSTS AND COST ANALYSIS; EPIDEMIOLOGIC METHODS; HUMANS; INFANT; MODELS, STATISTICAL; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; TURKEY; VACCINATION;

EID: 84872613794     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.071     Document Type: Article

References (30)

1. Tate J.E., Burton A.H., Boschi-Pinto C., Steele A.D., Duque J., Parashar U.D. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2011, 3099(11):1-6.
2. Bernstein D.I. Rotavirus overview. Pediatr Infect Dis J 2009, 28(3 Suppl.):S50-S53.
3. Ceyhan M., Alhan E., Salman N., Kurugol Z., Yildirim I., Celik U., et al. Multicenter prospective study on the burden of rotavirus gastroenteritis in Turkey, 2005-2006: a hospital-based study. J Infect Dis 2009, 200(Suppl. 1):S234-S238.
4. Kurugöl Z., Geylani S., Karaca Y., Umay F., Erensoy S., Vardar F., et al. Rotavirus gastroenteritis among children under five years of age in ýzmir, Turkey. Turkish J Pediatr 2003, 45:290-294.
5. Khoury H., Ogilvie I., El Khoury A.C., Duan Y., Goetghebeur M.M. Burden of rotavirus gastroenteritis in the Middle Eastern and North African pediatric population. BMC Infect Dis 2011, 11:9-20.
6. Karadag A., Acikgoz Z.C., Avci Z., Catal F., Gocer S., Gamberzade S., et al. Childhood diarrhoea in Ankara, Turkey: epidemiological and clinical features of rotavirus-positive versus rotavirus-negative cases. Scand J Infect Dis 2005, 37(4):269-275.
7. Akan H., Izbirak G., Gurol Y., Sari{dotless}kaya S., Gündüz T.S., Yi{dotless}lmaz G., et al. Rotavirus and adenovirus frequency among patients with acute gastroenteritis and their relationship to clinical parameters: a retrospective study in Turkey. Asia Pac Fam Med 2009, 8(1):8.
8. Van der Wielen M., Giaquinto C., Gothefors L., Huelsse C., Huet F., Littmann M., et al. Impact of community-acquired paediatric rotavirus gastroenteritis on family life: data from the REVEAL study. BMC Fam Pract 2010, 11:22.
9. Bilcke J., Beutels P. Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources. Pharmacoeconomics 2009, 27(4):281-297.
10. Jit M., Bilcke J., Mangen M.J., Salo H., Melliez H., Edmunds W.J., et al. The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine 2009, 27(44):6121-6128.
11. Atchison C., Lopman B., Edmunds W.J. Modelling the seasonality of rotavirus disease and the impact of vaccination in England and Wales. Vaccine 2010, 28(18):3118-3126.
12. Atkins K.E., Shim E., Pitzer V.E., Galvani A.P. Impact of rotavirus vaccination on epidemiological dynamics in England and Wales. Vaccine 2012, 30(3):552-564.
13. Standaert B., Parez N., Tehard B., Colin X., Detournay B. Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France. Appl Health Econ Health Policy 2008, 6(4):199-216.
14. Postma M.J., Jit M., Rozenbaum M.H., Standaert B., Tu H.A., Hutubessy R.C. Comparative review of three cost-effectiveness models for rotavirus vaccines in national immunization programs: a generic approach applied to various regions in the world. BMC Med 2011, 9:84.
15. Goossens L.M.A., Standaert B., Hartwig N., Hovels A.M., Al M.J. The cost-utility of rotavirus vaccination with Rotarix(TM) (RIX4414) in the Netherlands 1487. Vaccine 2008, 26(8):1118-1127.
16. Martin A., Batty A., Roberts J.A., Standaert B. Cost-effectiveness of infant vaccination with RIX4414 (Rotarix) in the UK. Vaccine 2009, 27(33):4520-4528.
17. Melliez H., Boelle P.Y., Baron S., Mouton Y., Yazdanpanah Y. Morbidity and cost of rotavirus infections in France. Med Mal Infect 2005, 35(10):492-499.
18. Turkish Statistical Institute. Turkey's statistical yearbook 2010. Report No. 3522; 2011.
19. Turkish Statistical Institute. Life expectancy at birth, ; 2012 [accessed 08.06.11]. http://www.tuik.gov.tr/Gosterge.do%3Fid=3712%26sayfa=giris%26metod=IlgiliGosterge.
20. Martin A., Cottrell S., Standaert B. Estimating utility scores in young children with acute rotavirus gastroenteritis in the UK. J Med Econ 2008, 11(3):471-484.
21. Turel O, Soysal A, Bakir M. Clinical characteristics and direct medical cost of diarrhea among hospitalised children in Istanbul. ISPOR. Ref Type: Abstract; 2005.
22. Turkish Social Security Institution. Social insurance and universal health insurance law, treatment guidelines. Appendix no. 8. Official Gazette of Republic of Turkey, Report no. 27532 (updated); 2010.
23. Vesikari T., Karvonen A., Prymula R., Schuster V., Tejedor J.C., Cohen R., et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007, 370(9601):1757-1763.
24. Jit M., Mangen M.-J.J., Melliez H., Bilcke J., Salo H., Edmunds W.J. An update to the cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine 2010, 28:7457-7459.
25. Gianino P., Mastretta E., Longo P., Laccisaglia A., Sartore M., Russo R., et al. Incidence of nosocomial rotavirus infections, symptomatic and asymptomatic, in breast-fed and non-breast-fed infants. J Hosp Infect 2002, 50(1):13-17.
26. Brisson M., Edmunds W.J. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decis Mak 2006, 26(5):434-446.
27. Brisson M., Edmunds W.J. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Mak 2003, 23(1):76-82.
28. Standaert B, Gomez J, Raes M, Debrus S, Velazquez FR, Postma MJ. Impact of rotavirus vaccination on hospitalisations in Belgium: comparing model predictions with observed data. PLoS One, in press. doi:10.1371/journal.pone.0053864.
29. Plosker G.L. Rotavirus vaccine RIX4414 (Rotarix): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developed countries. Pharmacoeconomics 2011, 29(5):439-454.
30. Plosker G.L. Rotavirus vaccine RIX4414 (Rotarix): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developing countries. Pharmacoeconomics 2011, 29(11):989-1009.